In essence, the Aduhelm coverage decision highlights a power struggle between Medicare and the FDA over access to prescription drug coverage for Americans. For Biogen, the coverage decision is a major blow to its plans for Aduhelm, which the company spent heavily on to develop. Additionally, Biogen is now being investigated over reports that it had a "back channel" into the FDA, which may have influenced the approval of Aduhelm.